A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis
CD40/CD154-interaction is critical in the development of Experimental Autoimmune Encephalomyelitis (EAE; mouse model of Multiple Sclerosis). Culprit CD4+CD40+ T cells drive a more severe form of EAE than conventional CD4 T cells. Blocking CD40/CD154-interaction with CD154-antibody prevents or ameliorates disease but had thrombotic complications in clinical trials. We targeted CD40 using a CD154-sequence based peptide. Peptides in human therapeutics demonstrate good safety. A small peptide, KGYY6, ameliorates EAE when given as pretreatment or at first symptoms.
Source: Journal of Neuroimmunology - Category: Allergy & Immunology Authors: Gisela M. Vaitaitis, Martin G. Yussman, David H. Wagner Source Type: research
More News: Allergy & Immunology | Autoimmune Disease | Brain | Clinical Trials | Multiple Sclerosis | Neurology